Skip to main content

Advertisement

SpringerLink
Log in

Thrombocytopenia after gemtuzumab is reversible by intravenous immunoglobulin

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Voutsadakis IA . Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anti-Cancer Drugs 2002; 13: 685–692.

    Article  CAS  Google Scholar 

  2. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al., Mylotarg Study Group. Efficacy and safety of Gemtuzumab Ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.

    Article  CAS  Google Scholar 

  3. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL et al., Mylotarg Study Group. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627–1636.

    Article  CAS  Google Scholar 

  4. Hansen RJ, Balthasar JP . Mechanisms of IVIG action in immune thrombocytopenic purpura. Clin Lab 2004; 50: 133–140.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong, Hong Kong

    A Y H Leung & R Liang

Authors
  1. A Y H Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Y H Leung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leung, A., Liang, R. Thrombocytopenia after gemtuzumab is reversible by intravenous immunoglobulin. Leukemia 19, 1077–1078 (2005). https://doi.org/10.1038/sj.leu.2403757

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403757

  • Springer Nature Limited

Search

Navigation